BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zelek WM, Xie L, Morgan BP, Harris CL. Compendium of current complement therapeutics. Mol Immunol 2019;114:341-52. [PMID: 31446305 DOI: 10.1016/j.molimm.2019.07.030] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 14.3] [Reference Citation Analysis]
Number Citing Articles
1 de Boer ECW, van Mourik AG, Jongerius I. Therapeutic Lessons to be Learned From the Role of Complement Regulators as Double-Edged Sword in Health and Disease. Front Immunol 2020;11:578069. [PMID: 33362763 DOI: 10.3389/fimmu.2020.578069] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Zelek WM. Measuring Total Classical Pathway and Activities of Individual Components of the Mouse Complement Pathway. Bio Protoc 2021;11:e4175. [PMID: 34722822 DOI: 10.21769/BioProtoc.4175] [Reference Citation Analysis]
3 Gomez-Arboledas A, Acharya MM, Tenner AJ. The Role of Complement in Synaptic Pruning and Neurodegeneration. Immunotargets Ther 2021;10:373-86. [PMID: 34595138 DOI: 10.2147/ITT.S305420] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Zarantonello A, Pedersen H, Laursen NS, Andersen GR. Nanobodies Provide Insight into the Molecular Mechanisms of the Complement Cascade and Offer New Therapeutic Strategies. Biomolecules 2021;11:298. [PMID: 33671302 DOI: 10.3390/biom11020298] [Reference Citation Analysis]
5 Agostinis C, Balduit A, Mangogna A, Zito G, Romano F, Ricci G, Kishore U, Bulla R. Immunological Basis of the Endometriosis: The Complement System as a Potential Therapeutic Target. Front Immunol 2020;11:599117. [PMID: 33505394 DOI: 10.3389/fimmu.2020.599117] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
6 Noris M, Daina E, Remuzzi G. Membranoproliferative glomerulonephritis: no longer the same disease and may need very different treatment. Nephrol Dial Transplant 2021:gfab281. [PMID: 34596686 DOI: 10.1093/ndt/gfab281] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Holden SS, Grandi FC, Aboubakr O, Higashikubo B, Cho FS, Chang AH, Forero AO, Morningstar AR, Mathur V, Kuhn LJ, Suri P, Sankaranarayanan S, Andrews-Zwilling Y, Tenner AJ, Luthi A, Aronica E, Corces MR, Yednock T, Paz JT. Complement factor C1q mediates sleep spindle loss and epileptic spikes after mild brain injury. Science 2021;373:eabj2685. [PMID: 34516796 DOI: 10.1126/science.abj2685] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Tremblay MÈ. Microglial functional alteration and increased diversity in the challenged brain: Insights into novel targets for intervention. Brain Behav Immun Health 2021;16:100301. [PMID: 34589793 DOI: 10.1016/j.bbih.2021.100301] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Chen JY, Galwankar NS, Emch HN, Menon SS, Cortes C, Thurman JM, Merrill SA, Brodsky RA, Ferreira VP. Properdin Is a Key Player in Lysis of Red Blood Cells and Complement Activation on Endothelial Cells in Hemolytic Anemias Caused by Complement Dysregulation. Front Immunol 2020;11:1460. [PMID: 32793201 DOI: 10.3389/fimmu.2020.01460] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
10 Rodrigues PRS, Picco N, Morgan BP, Ghazal P. Sepsis target validation for repurposing and combining complement and immune checkpoint inhibition therapeutics. Expert Opin Drug Discov 2021;16:537-51. [PMID: 33206027 DOI: 10.1080/17460441.2021.1851186] [Reference Citation Analysis]
11 Java A, Apicelli AJ, Liszewski MK, Coler-Reilly A, Atkinson JP, Kim AH, Kulkarni HS. The complement system in COVID-19: friend and foe? JCI Insight 2020;5:140711. [PMID: 32554923 DOI: 10.1172/jci.insight.140711] [Cited by in Crossref: 100] [Cited by in F6Publishing: 87] [Article Influence: 50.0] [Reference Citation Analysis]
12 Teçza M, Kagawa TF, Jain M, Cooney JC. Enzyme kinetic and binding studies identify determinants of specificity for the immunomodulatory enzyme ScpA, a C5a inactivating bacterial protease. Comput Struct Biotechnol J 2021;19:2356-65. [PMID: 33897974 DOI: 10.1016/j.csbj.2021.04.024] [Reference Citation Analysis]
13 Escamilla-Rivera V, Santhanakrishnan M, Liu J, Gibb DR, Forsmo JE, Foxman EF, Eisenbarth SC, Luckey CJ, Zimring JC, Hudson KE, Stowell SR, Hendrickson JE. Complement Plays a Critical Role in Inflammation-Induced Immunoprophylaxis Failure in Mice. Front Immunol 2021;12:704072. [PMID: 34249009 DOI: 10.3389/fimmu.2021.704072] [Reference Citation Analysis]
14 Ort M, Dingemanse J, van den Anker J, Kaufmann P. Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway. Front Immunol 2020;11:599417. [PMID: 33362783 DOI: 10.3389/fimmu.2020.599417] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Mongan D, Sabherwal S, Susai SR, Föcking M, Cannon M, Cotter DR. Peripheral complement proteins in schizophrenia: A systematic review and meta-analysis of serological studies. Schizophr Res 2020;222:58-72. [PMID: 32456884 DOI: 10.1016/j.schres.2020.05.036] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
16 Zelek WM, Morgan BP. Monoclonal Antibodies Capable of Inhibiting Complement Downstream of C5 in Multiple Species. Front Immunol 2020;11:612402. [PMID: 33424866 DOI: 10.3389/fimmu.2020.612402] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
17 Chen M, Edwards SR, Reutens DC. Complement in the Development of Post-Traumatic Epilepsy: Prospects for Drug Repurposing. J Neurotrauma 2020;37:692-705. [PMID: 32000582 DOI: 10.1089/neu.2019.6942] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
18 Polycarpou A, Howard M, Farrar CA, Greenlaw R, Fanelli G, Wallis R, Klavinskis LS, Sacks S. Rationale for targeting complement in COVID-19. EMBO Mol Med 2020;12:e12642. [PMID: 32559343 DOI: 10.15252/emmm.202012642] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 21.0] [Reference Citation Analysis]
19 Pedersen H, Jensen RK, Hansen AG, Gadeberg TAF, Thiel S, Laursen NS, Andersen GR. A C3-specific nanobody that blocks all three activation pathways in the human and murine complement system. J Biol Chem 2020;295:8746-58. [PMID: 32376685 DOI: 10.1074/jbc.RA119.012339] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
20 Wu K, Cao B, Wang C, Yang X, Zhao S, Diao T, Lin L, Zhao G, Zhou W, Yang J, Li K. The C5a/C5aR1 Axis Contributes to the Pathogenesis of Acute Cystitis Through Enhancement of Adhesion and Colonization of Uropathogenic E. coli. Front Cell Infect Microbiol 2022;12:824505. [DOI: 10.3389/fcimb.2022.824505] [Reference Citation Analysis]
21 Santiesteban-Lores LE, Carneiro MC, Isaac L, Bavia L. Complement System in Alcohol-Associated Liver Disease. Immunol Lett 2021;236:37-50. [PMID: 34111475 DOI: 10.1016/j.imlet.2021.05.007] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Zarantonello A, Presumey J, Simoni L, Yalcin E, Fox R, Hansen A, Olesen HG, Thiel S, Johnson MB, Stevens B, Laursen NS, Carroll MC, Andersen GR. An Ultrahigh-Affinity Complement C4b-Specific Nanobody Inhibits In Vivo Assembly of the Classical Pathway Proconvertase. J Immunol 2020;205:1678-94. [PMID: 32769120 DOI: 10.4049/jimmunol.2000528] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
23 Ruiz-Molina N, Parsons J, Müller M, Hoernstein SNW, Bohlender LL, Pumple S, Zipfel PF, Häffner K, Reski R, Decker EL. A synthetic protein as efficient multitarget regulator against complement over-activation. Commun Biol 2022;5:152. [PMID: 35194132 DOI: 10.1038/s42003-022-03094-5] [Reference Citation Analysis]
24 Schartz ND, Tenner AJ. The good, the bad, and the opportunities of the complement system in neurodegenerative disease. J Neuroinflammation 2020;17:354. [PMID: 33239010 DOI: 10.1186/s12974-020-02024-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
25 Mallah K, Couch C, Borucki DM, Toutonji A, Alshareef M, Tomlinson S. Anti-inflammatory and Neuroprotective Agents in Clinical Trials for CNS Disease and Injury: Where Do We Go From Here? Front Immunol 2020;11:2021. [PMID: 33013859 DOI: 10.3389/fimmu.2020.02021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
26 Giglhuber K, Berthele A. Eculizumab in the treatment of neuromyelitis optica spectrum disorder. Immunotherapy 2020;12:1053-66. [PMID: 32772617 DOI: 10.2217/imt-2020-0163] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Galindo-Izquierdo M, Pablos Alvarez JL. Complement as a Therapeutic Target in Systemic Autoimmune Diseases. Cells 2021;10:148. [PMID: 33451011 DOI: 10.3390/cells10010148] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
28 Sultan EY, Rizk DE, Kenawy HI, Hassan R. A small fragment of factor B as a potential inhibitor of complement alternative pathway activity. Immunobiology 2021;226:152106. [PMID: 34147816 DOI: 10.1016/j.imbio.2021.152106] [Reference Citation Analysis]
29 Sharma S, Bhatnagar R, Gaur D. Complement Evasion Strategies of Human Pathogenic Bacteria. Indian J Microbiol 2020;60:283-96. [PMID: 32655196 DOI: 10.1007/s12088-020-00872-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Lung T, Sakem B, Hemmerle A, Nydegger M, Risch M, Risch L, Nydegger U. Autoimmune diseases - New insights into a troublesome field. J Transl Autoimmun 2021;4:100108. [PMID: 34179743 DOI: 10.1016/j.jtauto.2021.100108] [Reference Citation Analysis]
31 Zelek WM, Menzies GE, Brancale A, Stockinger B, Morgan BP. Characterizing the original anti-C5 function-blocking antibody, BB5.1, for species specificity, mode of action and interactions with C5. Immunology 2020;161:103-13. [PMID: 32557571 DOI: 10.1111/imm.13228] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
32 Kurolap A, Hagin D, Freund T, Fishman S, Zunz Henig N, Brazowski E, Yeshaya J, Naiman T, Pras E, Ablin JN, Baris Feldman H. CD55-deficiency in Jews of Bukharan descent is caused by the Cromer blood type Dr(a-) variant. Hum Genet 2022. [PMID: 35314883 DOI: 10.1007/s00439-021-02428-3] [Reference Citation Analysis]
33 Zelek WM, Morgan BP. Targeting complement in neurodegeneration: challenges, risks, and strategies. Trends in Pharmacological Sciences 2022. [DOI: 10.1016/j.tips.2022.02.006] [Reference Citation Analysis]
34 Lokki AI, Heikkinen-Eloranta J. Pregnancy induced TMA in severe preeclampsia results from complement-mediated thromboinflammation. Hum Immunol 2021;82:371-8. [PMID: 33820656 DOI: 10.1016/j.humimm.2021.03.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
35 Kamala O, Malik TH, Hallam TM, Cox TE, Yang Y, Vyas F, Luli S, Connelly C, Gibson B, Smith-Jackson K, Denton H, Pappworth IY, Huang L, Kavanagh D, Pickering MC, Marchbank KJ. Homodimeric Minimal Factor H: In Vivo Tracking and Extended Dosing Studies in Factor H Deficient Mice. Front Immunol 2021;12:752916. [PMID: 34956184 DOI: 10.3389/fimmu.2021.752916] [Reference Citation Analysis]
36 Carr JM, Cabezas-Falcon S, Dubowsky JG, Hulme-Jones J, Gordon DL. Dengue virus and the complement alternative pathway. FEBS Lett 2020;594:2543-55. [PMID: 31943152 DOI: 10.1002/1873-3468.13730] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
37 Tradtrantip L, Asavapanumas N, Verkman AS. Emerging therapeutic targets for neuromyelitis optica spectrum disorder. Expert Opin Ther Targets 2020;24:219-29. [PMID: 32070155 DOI: 10.1080/14728222.2020.1732927] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
38 Zheng C, Ricci J, Zhang Q, Alawieh A, Yang X, Nadig S, He S, Engel P, Jin J, Atkinson C, Tomlinson S. Characterization of Novel P-Selectin Targeted Complement Inhibitors in Murine Models of Hindlimb Injury and Transplantation. Front Immunol 2021;12:785229. [PMID: 34899752 DOI: 10.3389/fimmu.2021.785229] [Reference Citation Analysis]
39 Barnum SR, Bubeck D, Schein TN. Soluble Membrane Attack Complex: Biochemistry and Immunobiology. Front Immunol 2020;11:585108. [PMID: 33240274 DOI: 10.3389/fimmu.2020.585108] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
40 Garlich J, Cinier M, Chevrel A, Perrocheau A, Eyerman DJ, Orme M, Kitten O, Scheibler L. Discovery of APL-1030, a Novel, High-Affinity Nanofitin Inhibitor of C3-Mediated Complement Activation. Biomolecules 2022;12:432. [DOI: 10.3390/biom12030432] [Reference Citation Analysis]
41 Gallo CG, Fiorino S, Posabella G, Antonacci D, Tropeano A, Pausini E, Pausini C, Guarniero T, Hong W, Giampieri E, Corazza I, Federico L, de Biase D, Zippi M, Zancanaro M. COVID-19, what could sepsis, severe acute pancreatitis, gender differences, and aging teach us? Cytokine 2021;148:155628. [PMID: 34411989 DOI: 10.1016/j.cyto.2021.155628] [Reference Citation Analysis]
42 Neef J, Palacios DS. Progress in mechanistically novel treatments for schizophrenia. RSC Med Chem 2021;12:1459-75. [PMID: 34671731 DOI: 10.1039/d1md00096a] [Reference Citation Analysis]
43 Halkjær L, Troldborg A, Pedersen H, Jensen L, Hansen AG, Hansen TK, Bjerre M, Østergaard JA, Thiel S. Complement Receptor 2 Based Immunoassay Measuring Activation of the Complement System at C3-Level in Plasma Samples From Mice and Humans. Front Immunol 2020;11:774. [PMID: 32431705 DOI: 10.3389/fimmu.2020.00774] [Reference Citation Analysis]
44 Willows J, Brown M, Sheerin NS. The role of complement in kidney disease. Clin Med (Lond) 2020;20:156-60. [PMID: 32188650 DOI: 10.7861/clinmed.2019-0452] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
45 Ng N, Powell CA. Targeting the Complement Cascade in the Pathophysiology of COVID-19 Disease. J Clin Med 2021;10:2188. [PMID: 34069355 DOI: 10.3390/jcm10102188] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
46 Plomp JJ, Huijbers MGM, Verschuuren JJGM, Borodovsky A. A bioassay for neuromuscular junction-restricted complement activation by myasthenia gravis acetylcholine receptor antibodies. J Neurosci Methods 2022;:109551. [PMID: 35247492 DOI: 10.1016/j.jneumeth.2022.109551] [Reference Citation Analysis]
47 Pasman R, Krom BP, Zaat SAJ, Brul S. The Role of the Oral Immune System in Oropharyngeal Candidiasis-Facilitated Invasion and Dissemination of Staphylococcus aureus. Front Oral Health 2022;3:851786. [DOI: 10.3389/froh.2022.851786] [Reference Citation Analysis]
48 Fattizzo B, Kulasekararaj AG. Second-Generation C5 Inhibitors for Paroxysmal Nocturnal Hemoglobinuria. BioDrugs 2020;34:149-58. [PMID: 31916226 DOI: 10.1007/s40259-019-00401-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
49 Gupta A, Gupta GS. Status of mannose-binding lectin (MBL) and complement system in COVID-19 patients and therapeutic applications of antiviral plant MBLs. Mol Cell Biochem 2021;476:2917-42. [PMID: 33745077 DOI: 10.1007/s11010-021-04107-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
50 Nasonov EL, Reshetnyak TM, Alekberova ZS. [Thrombotic microangiopathy in rheumatology: a link between thrombosis and autoimmunity]. Ter Arkh 2020;92:4-14. [PMID: 32598770 DOI: 10.26442/00403660.2020.05.000697] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
51 Talaat IM, Elemam NM, Saber-ayad M. Complement System: An Immunotherapy Target in Colorectal Cancer. Front Immunol 2022;13:810993. [DOI: 10.3389/fimmu.2022.810993] [Reference Citation Analysis]
52 Dalakas MC, Alexopoulos H, Spaeth PJ. Complement in neurological disorders and emerging complement-targeted therapeutics. Nat Rev Neurol 2020;16:601-17. [PMID: 33005040 DOI: 10.1038/s41582-020-0400-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
53 Howard JF Jr, Vissing J, Gilhus NE, Leite MI, Utsugisawa K, Duda PW, Farzaneh-Far R, Murai H, Wiendl H. Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody-Positive Generalized Myasthenia Gravis. Expert Opin Investig Drugs 2021;30:483-93. [PMID: 33792453 DOI: 10.1080/13543784.2021.1897567] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]